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ABSTRACT 
An individual‟s lipid profile is influenced by genetic variants and alcohol consumption, but the 
contribution of interactions between these exposures has not been studied. We therefore 
incorporated gene-alcohol interactions into a multi-ancestry genome-wide association study of 
levels of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and 
triglycerides. We included 45 studies in Stage 1 (genome-wide discovery) and 66 studies in 
Stage 2 (focused follow-up), for a total of 394,584 individuals from five ancestry groups. 
Genetic main and interaction effects were jointly assessed by a 2 degrees of freedom (DF) test, 
and a 1 DF test was used to assess the interaction effects alone. Variants at 495 loci were at least 
suggestively associated (P<1×10
-6
) with lipid levels in Stage 1 and were evaluated in Stage 2, 
followed by combined analyses of Stage 1 and Stage 2. In the combined analysis of Stage 1 and 
Stage 2, 147 independent loci were associated with lipid levels at P<5×10
-8
 using 2 DF tests, of 
which 18 were novel. No genome-wide significant associations were found testing the 
interaction effect alone. The novel loci included several genes (PCSK5, VEGFB, and A1CF) with 
a putative role in lipid metabolism based on existing evidence from cellular and experimental 
models. 
 
Keywords: Alcohol consumption, gene-environment interactions, gene-lifestyle interactions, 
genome-wide association study, lipid levels, cholesterol, triglycerides 
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Serum concentrations of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), and triglycerides (TG) are modifiable risk factors for cardiovascular 
disease, the leading cause of death globally (1). Lipid levels are influenced by multiple 
exposures, including genetic and lifestyle factors. The genetic factors  influencing lipid levels 
have been widely studied (2-8), and large-scale genome-wide association studies (GWAS) have 
identified 236 loci associated with HDL-C, LDL-C, and TG, which account for up to ~12 percent 
of the total trait variance in the studied populations (5, 7). 
Lifestyle factors, such as alcohol consumption, also associate considerably with lipid levels: in 
epidemiologic studies, higher alcohol consumption is associated with improved lipid profile, 
including associations with HDL-C levels, HDL particle concentration, and HDL-C subfractions 
(9, 10). The relationship between alcohol use and LDL-C or TG is less clear, with some studies 
reporting positive while others reported negative associations (11-20). A causal role of low-to-
moderate alcohol consumption in improving overall lipid profile is supported by intervention 
studies (19), and more recently by Mendelian randomization studies (21, 22). 
Potential modification of genetic effects on lipid levels by lifestyle exposures, including alcohol 
consumption, is relatively unexplored (23). Genetic association studies accounting for potential 
gene-alcohol interactions may lead to the identification of novel lipid loci and may reveal new 
biological insights that can potentially be explored for treatment or prevention of dyslipidemia. 
In order to investigate the potential modulating role of alcohol consumption in the genetic 
architecture of lipid levels, and identify novel HDL-C, LDL-C, and TG loci, we performed 
genome-wide gene-alcohol interaction meta-analyses of LDL-C, HDL-C and TG.  OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/advance-article-abstract/doi/10.1093/aje/kw
z005/5304469 by Q
ueen M
ary U
niversity of London user on 25 February 2019
21 
 
METHODS 
Overall design 
Table 1 shows the overall design of this study, conducted within the setting of the Cohorts for 
Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Gene-Lifestyle 
Interactions Working Group (24, 25). In order to decrease the computational burden we carried 
out genome-wide analyses in Stage 1, and followed up suggestively associated variants in Stage 
2, with the combined analysis of Stage 1 and Stage 2 serving as the primary analysis (26). We 
used two complementary approaches to model interactions: 1) a 2 degrees of freedom (DF) test 
was used to jointly assess both the genetic main effect and interaction effect on lipid levels, and 
2) a 1 DF test was used to assess the effect of interactions alone. The 2 DF test is more powerful 
when there is both a genetic main and interaction effect, and it may thus help identify interaction 
effects for which the 1 DF test is underpowered (27). 
Overview of participating studies 
This study includes men and women between the ages of 18-80 from five ancestry groups: 
European, African, Asian, Hispanic, and Brazilian. Each study obtained informed consent from 
participants and approval from the appropriate institutional review boards. Although the 
participating studies are based on different study designs and populations, all of them have data 
on lipid levels, alcohol consumption, and genotypes across the genome.  
In total, this study comprises 394,584 individuals. Stage 1 included 89,893 European, 20,989 
African, 12,450 Asian, and 3,994 Hispanic ancestry participants for an overall total of 127,326 
individuals from 45 studies (Web Table 1), namely: Age Gene/Environment Susceptibility 
Reykjavik Study (AGES: 1967 - Reykjavik, Iceland), Atherosclerosis Risk in Communities 
study (ARIC: 1987-1989 - Washington County, MD; Forsyth County, NC; Jackson, MS; and 
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Minneapolis, MN), Coronary Artery Risk Development in Young Adults (CARDIA: 1985-1986 
- Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA), Cardiovascular Health 
Study (CHS: 1989-1990 and 1992-1993 - Forsyth County, NC; Sacramento County, CA; 
Washington County, MD and Pittsburgh, PA), CROATIA-Korcula (2007 - Korcula, Croatia), 
CROATIA-Vis (2003-2004 - Vis, Croatia), Erasmus Rucphen Family study (ERF: 2002-2005 - 
Rotterdam, the Netherlands), FamHS (FamHS: 1992-1995 - Salt Lake City, UT; Forsyth County, 
NC; Minneapolis, MN; and Framingham, MA), Framingham Heart Study (Framingham: 1948 - 
Framingham, MA), Genetic Epidemiology Network of Arteriopathy (GENOA: 1995-2000 - 
Rochester, MN and Jackson, MS), Genetic Epidemiology Network of Salt Sensitivity (GenSalt: 
2003-2005 - Hebei; Henan; Shandong; Shaanxi; and Jiangsu, China), Generation Scotland: 
Scottish Family Health Study (GS:SFHS: 2006-2011 - Scotland), Health, Aging and Body 
Composition Study (HABC: 1997-1998 - Pittsburgh, PA and Memphis, TN), Healthy Aging in 
Neighborhoods of Diversity across the Life Span (HANDLS: 2004-2009 - Baltimore, MD), 
Health, Risk Factors, Exercise Training and Genetics (HERITAGE: 1995-2000 - AZ; IN; MN; 
TX; and Quebec, Canada), Howard University Family Study (HUFS: 2001-2008 - Washington, 
DC), Hypertension Genetic Epidemiology Network (HyperGEN: 1996-1999 - Birmingham, AL; 
Salt Lake City, UT; Forsyth County, NC; Minneapolis, MN; and Framingham, MA), Jackson 
Heart Study (JHS: 2000-2004 - Jackson, MS), Multi-Ethnic Study of Atherosclerosis (MESA: 
2000-2002 - Los Angeles, CA; St. Paul, MN; Chicago, IL; Winston-Salem, NC; Baltimore, MD 
and New York, NY), Netherlands Epidemiology of Obesity study (NEO: 2008-2012 - Leiden, 
the Netherlands), Rotterdam Study 1 (RS1: 1990 - Rotterdam, the Netherlands), Rotterdam 
Study 2 (RS2: 2000-2001 - Rotterdam, the Netherlands), Rotterdam Study 3 (RS3: 2006-2008 - 
Rotterdam, the Netherlands), Singapore Chinese Eye Study (SCES: 2009-2011 - Singapore), 
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Singapore Chinese Health Study (SCHS: 1993-1998 - Singapore), Singapore Malay Eye Study 
(SiMES: 2004-2006 - Singapore), Singapore Indian Eye Study (SINDI: 2007-2009 - Singapore), 
Singapore 2 (SP2-1M: 1982-1998 - Singapore), Women‟s Genome Health Study (WGHS: 1992-
1995 - USA), and Women‟s Health Initiative (WHI: 1993-1998 - USA). 
Stage 2 included 136,986 European, 4,475 African, 108,431 Asian, 13,714 Hispanic, and 3,652 
Brazilian ancestry individuals for an overall total of 267,258 individuals from the following 
studies (Web Table 2): 1982 Pelotas Birth Cohort Study (1982 - Pelotas, Brazil), African 
American Diabetes Heart Study (AA-DHS: 1998-2005 - Winston-Salem, NC), Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT: 1998-2000 - Denmark; Finland; Ireland; 
Norway; Sweden; UK), Baependi Heart Study  (2010 - Baependi, Brazil), BBJ (2003-2008 - 
Japan), Beijing Eye Study (2001 - Beijing, China), British Genetics of Hypertension (BRIGHT: 
1995 - UK), Cardio-metabolic Genome Epidemiology Network, Amagasaki Study (CAGE-
Amagasaki: 2002-2003 - Amagasaki, Japan), Data from an Epidemiological Study on the Insulin 
Resistance (DESIR-1: 1994-1996 - France), Dongfeng-Tongji Cohort Study (DF-TJ: 2008 - 
Shiyan city, China), Diabetes Heart Study (DHS: 1998-2005 - Winston-Salem, NC), Dose 
Responses to Exercise Training (DR's EXTRA: 2005-2006 - Kuopio, Finland), Estonian Genome 
Center - University of Tartu (EGCUT: 2002-2010 - Estonia), European Prospective Investigation 
into Cancer and Nutrition (EPIC: 1992-1997 - France; Italy; Spain; UK; the Netherlands; 
Germany; Sweden; Denmark; Norway; and Greece), Fenland Study (FENLAND-GWAS: 1950-
1975 - Cambridgeshire, England), Finland-United States Investigation of NIDDM Genetics 
(FUSION: 1994 - Finland), Genetic Studies of Atherosclerosis Risk (GeneSTAR: 1983-2006 - 
Baltimore, MD), Gene x Lifestyle Interactions and Complex Traits Involved in Elevated Disease 
Risk (GLACIER: 1985-2004 - Sweden), Genetic Regulation of Arterial Pressure of Humans in 
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the Community (GRAPHIC: 2003-2005 - Leicestershire, UK), Hispanic Community Health 
Study/ Study of Latinos (HCHS/SOL: 2008-2011 - Chicago, IL; Miami, FL; New York City, 
NY; and San Diego, CA), Health & Retirement Study (HRS: 2006-2010 - USA), Hypertension 
Genetic Epidemiology Network (HyperGEN-AXIOM: 1996-1999 - Birmingham, AL; Salt Lake 
City, UT; Forsyth County, NC; Minneapolis, MN; and Framingham, MA), Italian Network 
Genetic Isolates - Carlantino (INGI-CARL: 2005-2006 - Carlantino, Italy), Italian Network 
Genetic Isolates - Friuli-Venezia Giulia (INGI-FVG: 2013 - Friuli-Venezia Giulia, Italy), EPIC-
InterAct Case-Cohort Study (InterAct: 1991-2007 - France; Italy; Spain; UK; the Netherlands; 
Germany; Sweden; and Denmark), Insulin Resistance Atherosclerosis Study (IRASC and 
IRASFS: 1999-2005 - San Antonio, TX; San Luis Valley, CO), Cooperative Health Research in 
the Augsburg Region S3 (KORA_S3: 1994-1995 - Augsburg, Germany), Cooperative Health 
Research in the Augsburg Region S4 (KORA_S4: 1991-2001 - Augsburg, Germany), Lothian 
Birth Cohort 1936 (LBC1936: 2004-2007 - Lothian, Scotland), LifeLines (2006-2013 - the 
Netherlands), London Life Sciences Prospective Population study (LOLIPOP: 2003-2007 - 
London, England), Long Life Family Study (LLFS: 2006-2009 - Boston, MA; New York City, 
NY; Pittsburgh PA; and Denmark), Kingston Gene-by-environment (Loyola GxE: 1994-1995 - 
Kingston, Jamaica), Spanish Town (Loyola SPT: 1994-1995 - Kingston, Jamaica), Metabolic 
Syndrome In Men (METSIM: 2005-2010 - Kuopio, Finland), Netherlands Study of Depression 
and Anxiety (NESDA: 2004-2007 - the Netherlands), French obese cases (OBA: 2005 - France), 
Prevention of REnal and Vascular ENd stage Disease study (PREVEND: 1997-1998 - 
Groningen, Netherlands), Precocious Coronary Artery Disease (PROCARDIS: 2004-2008 - UK; 
Italy; Sweden; and Germany), Ragama Health Study (RHS: 2007 - Ragama, Sri Lanka), 
Stockholm Heart Epidemiology Program (SHEEP: 1992-1994 - Stockholm county, Sweden), 
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Study of Health in Pomerania (SHIP-0: 1997-2001 - Greifswald, Stralsund and Anklam 
Germany), Study of Health in Pomerania - Trend (SHIP-Trend: 2008-2012 - Greifswald, 
Stralsund and Anklam Germany), Shanghai Women's Health Study/ Shanghai Men's Health 
Study (SWHS/SMHS: 1997-2000 - Shanghai, China), TwinGene of the Swedish Twin Registry 
(TWINGENE: 2004-2008 - Sweden), and Cardiovascular Risk in Young Finns Study (YFS: 
1980 - Finland). 
Phenotype and lifestyle variables 
Three lipids traits were analyzed separately: HDL-C (mg/dL), LDL-C (mg/dL), and TG (mg/dL). 
HDL-C and TG were directly assayed, while LDL-C was either directly assayed or estimated 
using the Friedewald equation: LDL-C = TC – HDL-C – (TG / 5) (28). Only fasting samples (≥ 8 
hours) were used to assay TG, and the Friedewald equation was only used in samples with 
fasting TG ≤ 400 mg/dL. LDL-C values were adjusted for use of statins (Web Appendix). HDL-
C and TG were natural log transformed prior to analyses. 
Alcohol consumption was assessed using two dichotomized alcohol consumption variables: 
„current drinking‟ status, defined as any recurrent drinking behavior, and „regular drinking‟ 
status, as the subset of current drinkers who consume at least two drinks per week. Because the 
standard pure ethanol content in one alcoholic drink may vary among countries, for this study a 
standard drink was defined to contain approximately 13g of pure ethanol, and this measure was 
used to standardize the definitions across studies.  
Genotyping and imputation 
Information on genotyping and imputation for each of the Stage 1 and Stage 2 studies are 
presented in Web Table 3 and Web Table 4, respectively. For imputation, most studies used the 
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1000 Genomes Project Phase I Integrated Release Version 3 Haplotypes (2010-11 data freeze, 
2012-03-14 haplotypes), which contain haplotypes for 1,092 individuals from multiple ancestry 
groups (29).  
Study-specific analysis 
Study-specific regression analyses were performed for each variant, using models containing the 
genetic variant, alcohol consumption variable (current drinking or regular drinking status), and 
their interaction. Variants were coded according to the additive model, so that the beta 
coefficient represents the effect size per copy of the coded allele. These regressions were 
adjusted for age, sex, ancestry-informative principal components, and study-specific variables 
where appropriate (such as center for multi-center studies). Information on principal components 
and study-specific variables adjusted for in each study-specific analysis is provided in Web 
Tables 3-4. 
Each study in Stage 1 performed genome-wide association analyses within each ancestry and 
provided the estimated genetic main effect, estimated interaction effect and a robust estimate of 
the corresponding covariance matrix. Each study in Stage 2 performed analyses only for the 
selected variants identified in Stage 1. Study-specific association analyses were performed using 
various software (Web Appendix and Web Tables 3-4). Extensive quality control using the R 
package EasyQC was performed for all study-specific GWAS results, as described in the Web 
Appendix (30).  
Meta-analysis 
We implemented METAL to meta-analyze the genetic main and interaction effects jointly using 
the 2 DF approach by Manning et al. (27, 31), and to meta-analyze the interaction coefficients 
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alone using inverse-variance weighted meta-analysis (1 DF test). For each meta-analysis, results 
were obtained from Wald tests, calculated using genetic main effect estimates, interaction effect 
estimates, and robust estimates of the corresponding covariance matrix.
 
In Stage 1 ancestry-specific meta-analyses were performed for each of the 12 analyses (3 lipids × 
2 alcohol consumption exposures × 2 tests). Genomic control correction was applied twice (32), 
first to the study-specific GWAS results (Web Table 5), and then to the ancestry-specific meta-
analysis results. The results from each ancestry group were then combined in a trans-ancestry 
meta-analysis.  
The variants that were at least suggestively associated (P-value < 1×10
-6
) in any of Stage 1 
interaction analyses were pursued for Stage 2 analysis. In Stage 2, we used the same approaches 
as in Stage 1 to perform ancestry-specific and trans-ancestry meta-analyses. Finally, ancestry-
specific and trans-ancestry meta-analyses were performed to combine Stage 1 results with Stage 
2 results. Variants with P-value < 5×10
-8
 for either the 2 DF joint test of genetic main and 
interaction effects or the 1 DF test of interaction effects were considered genome-wide 
significant. False discovery rate (FDR) q-values were calculated using the Benjamini and 
Hochberg method implemented in the “p.adjust” function in R, correcting for the number of tests 
performed in Stage 1. FDR q-values < 0.05 thus indicate a < 5% false discovery rate even after 
considering the multiple testing introduced by performing genome-wide analyses on multiple 
outcomes using multiple models. An independent locus was defined as the ±1 Mbp region 
surrounding an index variant. For each locus the closest genes were determined based on 
proximity to the index variant. For loci with intergenic index variants we provided the closest 
gene in each direction. 
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Additional analyses 
The percent of variance explained in HDL-C, LDL-C, and TG by all previously known and 
novel variants was evaluated in ten studies from multiple ancestries (Web Appendix). 
HaploReg, RegulomeDB, and Genotype-Tissue Expression (GTEx) were used to annotate 
variants at significant loci (33-35). We also used the Data-driven Expression Prioritized 
Integration for Complex Traits (DEPICT) software to prioritize genes at the loci associated with 
lipid levels in the combined analysis of Stage 1 and 2. More details on gene prioritization using 
DEPICT can be found in the Web Appendix.  
Lastly, we examined the association of index variants at the 147 significant loci with coronary 
artery disease and myocardial infarction using publicly available summary association results 
from a large GWAS of these phenotypes performed by the CARDIoGRAMplusC4D consortium 
(36).  
RESULTS 
Descriptive statistics of the studies participating in Stage 1 are shown in Web Table 1: 56.1 
percent of Stage 1 participants were current drinkers and 39.9 percent were regular drinkers. The 
Stage 1 genome-wide analyses identified 25,115 variants in 495 independent loci that were at 
least suggestively associated (P-value < 1×10
-6
) with HDL-C, LDL-C, or TG using either the 1 
DF test of the interaction or the 2 DF test that jointly assesses genetic main and interaction 
effects. The 1 DF interaction test identified 356 suggestively associated variants, while the 2 DF 
joint test identified an additional 24,759. Manhattan and quantile-quantile plots are shown in 
Web Figures 1 and 2, respectively. OR
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The 25,115 variants were then evaluated in Stage 2. Descriptive statistics of the studies 
participating in Stage 2 are shown in Web Table 2: 58.5 percent of Stage 2 participants were 
current drinkers and 41.0 percent were regular drinkers. The combined analysis of Stage 1 and 
Stage 2 identified 22,590 variants at 147 independent loci at genome-wide significance (P-value 
< 5×10
-8
, Web Table 6). All genome-wide significant associations were identified through the 2 
DF joint tests of main and interaction effects. There were no genome-wide significant 1 DF 
interaction associations in the combined analysis of Stage 1 and Stage 2. At genome-wide 
significance, 95 of the 147 loci were associated with HDL-C, 66 were associated with LDL-C, 
and 58 were associated with TG. Out of the 147 loci, 60 loci were associated with more than one 
lipid trait, as shown in a Venn diagram in Figure 1.  
Novel loci 
Of the 147 identified genome-wide significant loci, 18 are novel lipid loci that have not been 
previously identified by other association studies for HDL-C, LDL-C, TG, or total cholesterol 
(Table 2 and Web Figure 3) (2-8). A concurrent genetic association study of exonic variants 
also identified four of these 18 novel loci (37), as indicated in Table 2. Eight of the novel loci 
involved HDL-C, eight involved LDL-C, and seven involved TG, as shown in the heatmap in 
Figure 2. The most significant associations at each of the 18 novel loci all had FDR q-values < 
0.05 (Table 2), indicating that they are unlikely to be false positives introduced by multiple 
testing. As shown in forest plots (Web Figure 4), the 2 DF associations at the novel loci were 
predominantly driven by genetic main effects, with a smaller contribution from interaction 
effects. Furthermore, of the 18 index variants, 15 had at least suggestively significant (P < 1×10
-
6
) genetic main effects in Stage 1 (Web Appendix and Web Table 7). None of the associations 
at the 18 novel loci displayed heterogeneity across ancestry groups (Table 2). 
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Known loci 
The remaining 129 of the 147 significant loci had been identified in previous GWAS of lipid 
traits (Web Table 6) (2-8). This is a subset of all known lipid loci: Web Table 8 shows the 
significance of 314 reported index variants in all 236 known lipid loci among all 2 DF joint tests 
and 1 DF interaction tests of the combined analysis of Stage 1 and Stage 2, or Stage 1 alone for 
variants not meeting the Stage 2 inclusion criteria (2-8). Considering only the 314 known 
variants, no 1 DF interactions were significant in the European, African, or trans-ancestry meta-
analyses (P-value < 8.8×10
-6
, corresponding to 0.05 / [314 variants × 3 lipid traits × 2 alcohol 
consumption variables × 3 ancestry groups]). 
Additional analyses 
The percentage of variance in LDL-C, HDL-C, and TG explained by various loci was calculated 
in individual studies from multiple ancestries. Across ancestry groups, the mean variance 
explained by known lipid loci was 9.1 percent for HDL-C, 10.4 percent for LDL-C, and 7.5 
percent for TG. The total percentage of additional variance explained by the 18 novel loci, 
including both genetic main and interaction effects, was 0.2 for HDL-C, 0.3 for LDL-C, and 0.4 
for TG. Ancestry-specific and study-specific estimates are shown in Web Table 9. 
Functional annotations using HaploReg (33) and RegulomeDB (34) for variants at the 147 loci 
that were associated in the combined analysis of Stage 1 and 2 are presented in Web Table 10, 
and associations of these variants with gene expression levels from the GTEx database (35) in a 
variety of tissues are shown in Web Table 11. A total of 443 variants were associated with gene 
expression levels, of which 27 variants were indicated by RegulomeDB as having strong 
evidence for an effect on enhancer function.  
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Our gene prioritization analyses with DEPICT highlighted (FDR q-values < 5 percent) 165 genes 
at HDL-C associated loci, 110 genes at LDL-C associated loci and 87 genes at TG associated 
loci (Web Tables 11-14). Thus, at some loci multiple potential causal genes were prioritized. 
DEPICT identified 656, 877 and 497 reconstituted gene sets that were significantly enriched 
(FDR q-values < 5 percent) for genes at HDL-C, LDL-C and TG loci, respectively (Web Table 
15). This large number of processes and enriched gene sets underscores the complex genetic, 
biological and physiological mechanisms underlying lipid traits. Among the most significantly 
enriched gene sets were processes related to “total amount of body fat” and “abnormal liver 
morphology”. Finally, DEPICT revealed that genes at associated HDL-C, LDL-C or TG loci 
were significantly enriched (FDR q-values < 5 percent) for association with gene expression in 
23 tissues, 14 cell-types and 12 physiological systems (Web Table 16). We found a compelling 
enrichment of genes acting in hepatocytes and liver processes at associated loci for each of the 
three traits and of genes acting in adipose tissues for HDL-C and TG loci (Web Table 16, Web 
Figure 5).  
Fourteen index variants at known lipid loci were associated with coronary artery disease with P-
value < 1.7×10
-4
 (0.05 / [147 variants × 2 disease outcomes]), and eleven of these were also 
associated with myocardial infarction (Web Table 17) (36). None of the index variants at novel 
loci were significantly associated with these clinical endpoints. 
DISCUSSION 
We performed a genome-wide association study of lipid levels incorporating interactions with 
alcohol consumption and identified 147 genome-wide significant lipid loci of which 18 are 
novel.   
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Despite the large sample of 394,584 individuals, which is comparable to other successful genetic 
interaction studies (38, 39), genome-wide significant interactions were not found in the present 
study. Gene-alcohol interactions also do not appear to have contributed substantially to the 
discovery of the 18 novel loci, given that the genetic main effect of index variants at 15 of the 18 
novel loci passed the Stage 1 suggestive significance threshold. We highlight three of the novel 
loci below that harbor especially promising candidate genes with putative roles in lipid 
metabolism based on existing evidence from cellular and experimental models. 
One of the newly identified associations for LDL-C maps to Proprotein Convertase 
Subtilisin/Kexin Type 5 (PCSK5), a member of the same gene family as PCSK9, which is 
targeted by new drugs that successfully lower LDL-C levels (40, 41). Several independent lines 
of evidence support the involvement of PCSK5 in the regulation of lipid levels. First, a candidate 
gene study found that variants in PCSK5 were associated with levels of HDL-C levels (42). 
Additionally, in vitro studies of cell lines show that PCSK5 inactivates endothelial lipase directly 
through cleavage, and that it may also inactivate endothelial lipase and lipoprotein lipase 
indirectly through activation of Angiopoietin-like 3 (43). Endothelial lipase, lipoprotein lipase, 
and Angiopoietin-like 3 have all been robustly implicated in the regulation of lipid levels, likely 
with primary roles in the metabolism of HDL-C and triglycerides (3, 44-46). In our study, the 
PCSK5 locus was only associated at genome-wide significance with LDL-C levels, and at 
nominal significance (P-value < 0.05) with TG levels.    
One novel locus for TG mapped to the A1CF gene, which encodes APOBEC1 Complementation 
Factor. Liu et al. also identified the same index variant (rs41274050) in association with TG in a 
concurrent study (37). They showed that introducing the minor allele of rs41274050 in mice led 
to increased TG levels, confirming the functional role of this missense variant in the regulation 
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of TG levels (37). APOBEC1 Complementation Factor forms an enzymatic complex with 
APOBEC1 and deaminates Apolipoprotein B mRNA (47). This site specific deamination of C to 
U results in the production of the apoB48 isoform as opposed to the apoB100 isoform (47). The 
apoB48 isoform is critical in the assembly and secretion of chylomicrons, which mainly carry 
dietary-derived triglycerides (48). Interestingly, a recent GWAS in individuals of East Asian 
ancestry identified the APOBEC1 locus for HDL-C levels (5), an association that we confirmed 
in our analysis (index variant: 12:7725904:ID). At nominal significance both the index variants 
near A1CF and APOBEC1 were associated with all three lipid traits (P-value < 0.05). Given the 
role of apoB100 in atherosclerosis, promoting the synthesis of apoB48 instead of apoB100 may 
represent a possible therapeutic strategy for the prevention of cardiovascular disease (49). 
Neither the index variant at A1CF nor APOBEC1 is significantly associated with coronary artery 
disease or myocardial infarction in the largest GWAS of these outcomes. However, further 
studies are needed to characterize their role in cardiovascular disease, given our multi-ancestry 
design and the European-driven design of the available GWAS data on cardiovascular disease 
outcomes (Web Table 17).  
Variants closest to the MACRO Domain Containing 1 (MACROD1) gene were associated with 
HDL-C levels and TG levels. This locus was also reported in the concurrent study by Liu et al. 
(37), although the index variant in their study was located in the Phospholipase C Beta 3 
(PLCB3) gene, around 120 Kbp away from the index variant in the present study. We found that 
variants at this locus were associated with expression levels of another nearby gene, Vascular 
Endothelial Growth Factor B (VEGFB), in adipose and heart tissue (Web Table 11). VEGF-B is 
reportedly involved in endothelial fatty acid transport, with Vegfb
-/-
 mice showing less 
accumulation of lipids in muscle, heart, and brown adipose tissue, but a greater uptake of fatty 
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acids in white adipose tissue, and higher body weight (50). Additionally, inhibition of VEGF-B 
in a mouse model of type 2 diabetes resulted in improved glycemic profile as well as a reduction 
of dyslipidemia (51). Mice lacking VEGF-B had lower levels of TG and LDL-C accompanied by 
higher levels of HDL-C. Subsequent studies on other mouse models did not corroborate these 
findings: Dijkstra et al. found in an independent strain of mice that knocking out VEGF-B had 
no effect on TG and total cholesterol levels (52), while Rubciuc et al. reported that transduction 
of the human VEGFB gene into mice led to increased vascularity in adipose tissue, and improved 
lipid profile (53, 54). Our results provide insight into the effects of VEGF-B in humans to 
complement the divergent reports from rodent studies. The A allele of index variant rs190528931 
is associated with decreased expression of VEGFB in adipose and heart tissue, decreased levels 
of HDL-C and increased levels of TG. Additionally, rs190528931 was also associated with 
nominally significant increased levels of LDL-C (P-value < 0.05). Hence, evidence from our 
study suggests that inhibition of VEGF-B does not improve lipid profile, but instead promotes 
dyslipidemia.  
The strengths of this study include the large sample size and diverse ancestral composition of the 
sample, and the use of a dense reference panel for genotype imputation (55). A limitation of this 
study is the imbalance in ancestry groups between Stage 1 and Stage 2. African ancestry 
individuals were well-represented in Stage 1 but underrepresented in Stage 2. In contrast, Asian 
and Hispanic ancestry individuals were relatively underrepresented in Stage 1 compared to Stage 
2. A more balanced division of participants across Stage 1 and Stage 2 may have led to the 
identification of additional loci. Additionally, alcohol consumption may be underreported in both 
self-administered questionnaires and interviews, leading to a loss of statistical power due to 
misclassification (56). Similarly, the classification of alcohol consumption into categories such 
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as regular drinkers and current drinkers may have reduced power relative to treating it as a fully 
quantitative variable (57). Nevertheless, the use of such categories was necessary for 
harmonizing data from 111 studies with heterogeneous measurement of alcohol consumption. It 
is plausible that more comprehensive characterization of alcohol consumption could reveal 
interactions that were missed in our study.  
In conclusion, we identified 18 novel loci that were significantly associated with lipid traits, and 
these include several loci with genes (PCSK5, VEGFB, and A1CF) that have a putative role in 
lipid metabolism based on existing evidence from cellular and experimental models. The 
associations identified in this study appear to be driven by genetic main effects and it remains 
uncertain whether alcohol consumption modifies the effect of genetic variants on lipid levels.  
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Diagnostics and Therapeutics, Research Institute, National Center for Global Health and 
Medicine, Tokyo, Japan (Fumihiko Takeuchi, Norihiro Kato); Department of Public Health 
Sciences, Loyola University Chicago, Maywood, Illinois (Bamidele O Tayo); Department of 
Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, 
Skåne University Hospital, Malmö, Sweden (Tibor V Varga, Paul W Franks); Department of 
Population and Quantitative Health and Sciences, Case Western Reserve University, Cleveland, 
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/advance-article-abstract/doi/10.1093/aje/kw
z005/5304469 by Q
ueen M
ary U
niversity of London user on 25 February 2019
41 
 
Ohio (Yajuan Wang, Jingjing Liang, Xiaofeng Zhu); Survey Research Center, Institute for Social 
Research, University of Michigan, Ann Arbor, Michigan (Erin B Ware, Jessica D Faul, Jennifer 
A Smith, David R Weir); Division of Epidemiology, Department of Medicine, Vanderbilt 
University School of Medicine, Nashville, Tennessee (Wanqing Wen, Xiao-Ou Shu, Wei 
Zheng); Division of General Internal Medicine, Department of Medicine, Johns Hopkins 
University School of Medicine, Baltimore, Maryland (Lisa R Yanek, Diane M Becker); 
Department of Cardiology, Ealing Hospital, Middlesex, United Kingdom (Weihua Zhang, John 
C Chambers, Jaspal S Kooner); McKusick-Nathans Institute of Genetic Medicine, Johns 
Hopkins University School of Medicine, Baltimore, Maryland (Dan E Arking); Ophthalmology 
& Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, 
Singapore, Singapore (Tin Aung, Tien Yin Wong); Section of Cardiovascular Research, Baylor 
College of Medicine, Houston, Texas (Christie Ballantyne); Houston Methodist Debakey Heart 
and Vascular Center, Houston, Texas (Christie Ballantyne); Department of Epidemiology, 
Human Genetics, and Environmental Sciences, The University of Texas School of Public Health, 
Houston, Texas (Eric Boerwinkle, James E Hixson); Human Genome Sequencing Center, Baylor 
College of Medicine, Houston, Texas (Eric Boerwinkle); Section of Genomic Pediatrics, 
Department of Pediatrics, Medicine and Physiology, Medical College of Wisconsin, Milwaukee, 
Wisconsin (Ulrich Broeckel); Centre for Genomic & Experimental Medicine, Institute of 
Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom (Archie 
Campbell); Ninewells Hospital & Medical School, University of Dundee, Dundee, Scotland, 
United Kingdom (John M Connell); Cardiovascular Division, Department of Medicine, 
Washington University, St. Louis, Missouri (Lisa de las Fuentes); Clinical Epidemiology, Leiden 
University Medical Center, Leiden, Netherlands (Renée de Mutsert, Dennis O Mook-Kanamori); 
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Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka (H 
Janaka de Silva); Center on Diabetes, Obesity, and Metabolism, Gerontology and Geriatric 
Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina (Jingzhong 
Ding); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and 
Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (Anna F 
Dominiczak); Department of Genetics, University of North Carolina, Chapel Hill, North 
Carolina (Qing Duan, Karen L Mohlke); Department of Family Medicine and Epidemiology, 
Alpert Medical School of Brown University, Providence, Rhode Island (Charles B Eaton); 
Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the 
West Indies, Mona, Jamaica (Terrence Forrester, Colin A McKenzie); Institute of Social and 
Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (Oscar H Franco); Braun 
School of Public Health, Hebrew University-Hadassah Medical Center, Jerusalem, Israel 
(Yechiel Friedlander); Department of Genetics, School of Medicine, Mashhad University of 
Medical Sciences, Mashhad, Iran (Mohsen Ghanbari); Preventive Medicine, Brigham and 
Women's Hospital, Boston, Massachusetts (Franco Giulainini, Lynda M Rose, Paul M Ridker, 
Daniel I Chasman); Department Psychiatry and Psychotherapy, University Medicine Greifswald, 
Greifswald, Germany (Hans J Grabe); Laboratory of Epidemiology and Population Sciences, 
National Institute on Aging, National Institutes of Health, Bethesda, Maryland (Tamara B Harris, 
Lenore J Launer); Institute of Biomedicine, School of Medicine, University of Eastern Finland, 
Kuopio Campus, Finland (Sami Heikkinen, Timo A Lakka); Department of Paediatrics, Yong 
Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore (Chew-
Kiat Heng); Khoo Teck Puat – National University Children's Medical Institute, National 
University Health System, Singapore, Singapore (Chew-Kiat Heng); Laboratory of Genome 
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Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, 
Minato-ku, Japan (Makoto Hirata); MedStar Health Research Institute, Hyattsville, Maryland 
(Barbara V Howard); Center for Clinical and Translational Sciences and Department of 
Medicine, Georgetown-Howard Universities, Washington, District of Columbia (Barbara V 
Howard); Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 
Rotterdam, The Netherlands (M Arfan Ikram); Department of Neurology, Erasmus University 
Medical Center, Rotterdam, The Netherlands (M Arfan Ikram); Division of Epidemiology & 
Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota 
(David R Jacobs Jr, Pamela J Schreiner); Collaborative Health Studies Coordinating Center, 
University of Washington, Seattle, Washington (Craig Johnson); Department of Ophthalmology, 
Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany (Jost Bruno Jonas); 
Beijing Institute of Ophthalmology, Beijing Ophthalmology and Visual Science Key Lab, 
Beijing Tongren Eye Center, Capital Medical University, Beijing, China (Jost Bruno Jonas); 
Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, 
Pittsburgh, Pennsylvania (Candace M Kammerer); Department of Clinical Gene Therapy, Osaka 
University Graduate School of Medicine, Suita, Japan (Tomohiro Katsuya); Department of 
Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan 
(Tomohiro Katsuya); Department of Biochemistry, National University of Singapore, Singapore, 
Singapore (Chiea Chuen Khor); Novo Nordisk Foundation Center for Basic Metabolic Research, 
Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of 
Copenhagen, Copenhagen, Denmark (Tuomas O Kilpeläinen); Department of Environmental 
Medicine and Public Health, The Icahn School of Medicine at Mount Sinai, New York, New 
York (Tuomas O Kilpeläinen); Duke-NUS Medical School, Singapore, Singapore (Woon-Puay 
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Koh, E Shyong Tai); Department of Health, National Institute for Health and Welfare, Helsinki, 
Finland (Heikki A Koistinen); Department of Medicine and Abdominal Center: Endocrinology, 
University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland (Heikki A 
Koistinen); Minerva Foundation Institute for Medical Research, Helsinki, Finland (Heikki A 
Koistinen); Department of Public Health, Department of Medicine, University of Split, Split, 
Croatia (Ivan Kolcic, Ozren Polasek); Fred Hutchinson Cancer Research Center, University of 
Washington School of Public Health, Seattle, Washington (Charles Kooperberg, Alex P Reiner); 
Sticht Center for Health Aging and Alzheimer's Prevention, Department of Internal Medicine, 
Wake Forest School of Medicine, Winston-Salem, North Carolina (Steve B Kritchevsky); Center 
for Integrative Medical Sciences, RIKEN, Yokohama, Japan (Michiaki Kubo); Department of 
Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland (Timo 
A Lakka); Cardiovascular Health Research Unit, Medicine, University of Washington, Seattle, 
Washington (Rozenn N Lemaitre); Epidemiology, Department of Preventive Medicine, 
Northwestern University Feinberg School of Medicine, Chicago, Illinois (Kiang Liu); 
Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research, 
Singapore (Marie Loh); Department of Biostatistics, University of Washington, Seattle, 
Washington (Tin Louie, Kenneth Rice); Biostatistics Section, Center for Public Health 
Genomics, University of Virginia, School of Medicine, West Complex, Charlottesville, Virginia 
(Ani W Manichaikul); Institute of Human Genetics, Helmholtz Zentrum München, German 
Research Center for Environmental Health, Neuherberg, Germany (Thomas Meitinger); Institute 
of Human Genetics, Technische Universität München, Munich, Germany (Thomas Meitinger); 
Department of Psychiatry, Amsterdam Neuroscience and Amsterdam Public Health Research 
Institute, Amsterdam University Medical Center, Amsterdam, The Netherlands (Yuri 
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Milaneschi, Brenda Penninx); Geriatrics, Medicine, University of Mississippi Medical Center, 
Jackson, Mississippi (Thomas H Mosley Jr); General Medicine & Primary Care, Medicine, Beth 
Israel Deaconess Medical Center, Boston, Massachusetts (Kenneth J Mukamal); Data Tecnica 
International, Glen Echo, Maryland (Mike A Nalls); Laboratory of Neurogenetics, National 
Institute on Aging, Bethesda, Maryland (Mike A Nalls); Cardiovascular Health Research Unit, 
Division of Cardiology, University of Washington, Seattle, Washington (Nona Sotoodehnia); 
Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, 
Baltimore, Maryland (Jeff R O‟Connell); Program for Personalized and Genomic Medicine, 
University of Maryland School of Medicine, Baltimore, Maryland (Jeff R O‟Connell); 
Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina (Nicholette D 
Palmer, Donald W Bowden); DZHK (German Centre for Cardiovascular Research), partner site 
Munich Heart Alliance, Neuherberg, Germany (Annette Peters); Psychiatric Hospital "Sveti 
Ivan", Zagreb, Croatia (Ozren Polasek); Gen-info Ltd, Zagreb, Croatia (Ozren Polasek); School 
of Public Health, Imperial College London, London, United Kingdom (Neil Poulter); Division of 
Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, 
California (Leslie J Raffel); Department of Clinical Physiology and Nuclear Medicine, Turku 
University Hospital, Turku, Finland (Olli T Raitakari); Research Centre of Applied and 
Preventive Cardiovascular Medicine, University of Turku, Turku, Finland (Olli T Raitakari); 
Center for Public Health Genomics, University of Virginia, School of Medicine, West Complex, 
Charlottesville, Virginia (Stephen S Rich); Institute for Maternal and Child Health - IRCCS 
"Burlo Garofolo", Trieste, Italy (Antonietta Robino, Paolo Gasparini); Department of 
Epidemiology and Medicine, University of Iowa, Iowa City, Iowa (Jennifer G Robinson); Centre 
for Global Health Research, Usher Institute of Population Health Sciences and Informatics, 
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University of Edinburgh, Edinburgh, United Kingdom (Igor Rudan); Institute for Community 
Medicine, University Medicine Greifswald, Greifswald, Germany (Carsten O Schmidt); National 
Heart and Lung Institute, Imperial College London, London, United Kingdom (William R Scott, 
Peter Sever, Jaspal S Kooner, James Scott); Division of Research, Kaiser Permanente of 
Northern California, Oakland, California (Stephen Sidney); Division of Population Health and 
Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, United 
Kingdom (Blair H Smith); Alzheimer Scotland Dementia Research Centre, The University of 
Edinburgh, Edinburgh, United Kingdom (John M Starr); Institute of Genetic Epidemiology, 
Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, 
Germany (Konstantin Strauch); Chair of Genetic Epidemiology, IBE, Faculty of Medicine, 
LMU, Munich, Germany (Konstantin Strauch); Life Sciences Institute, National University of 
Singapore, Singapore, Singapore (Yik Ying Teo); NUS Graduate School for Integrative Science 
and Engineering, National University of Singapore, Singapore, Singapore (Yik Ying Teo); 
Department of Statistics and Applied Probability, National University of Singapore, Singapore, 
Singapore (Yik Ying Teo); Department of Internal Medicine, Erasmus University Medical 
Center, Rotterdam, The Netherlands (André G Uitterlinden); Beijing Tongren Eye Center, 
Beijing Tongren Hospital, Capital Medical University, Beijing, China (Wen Bin Wei); Jackson 
Heart Study, School of Public Health, Jackson State University, Jackson, Mississippi (Gregory 
Wilson Sr); Department of Epidemiology, Graduate School of Public Health, University of 
Pittsburgh, Pittsburgh, Pennsylvania (Jian-Min Yuan); Division of Cancer Control and 
Population Sciences, UPMC Hillman Cancer, University of Pittsburgh, Pittsburgh, Pennsylvania 
(Jian-Min Yuan); Behavioral Epidemiology Section, Laboratory of Epidemiology and Population 
Sciences, National Institute on Aging, National Institutes of Health, Baltimore, Maryland (Alan 
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B Zonderman); Lee Kong Chian School of Medicine, Nanyang Technological University, 
Singapore, Singapore (John C Chambers); Imperial College Healthcare NHS Trust, London, 
United Kingdom (John C Chambers, Jaspal S Kooner); MRC-PHE Centre for Environment and 
Health, Imperial College London, London, United Kingdom (John C Chambers, Paul Elliott); 
NIHR Imperial College Biomedical Research Centre, Imperial College London, London, United 
Kingdom (John C Chambers, Paul Elliott, Jaspal S Kooner); Psychology, The University of 
Edinburgh, Edinburgh, United Kingdom (Ian J Deary); Broad Institute of the Massachusetts 
Institute of Technology and Harvard University, Boston, Massachusetts (Tõnu Esko); 
Department of Nutrition, Harvard T. H. Chan School of Public Health, Harvard University, 
Boston, Massachusetts (Paul W Franks, Rob M van Dam); Department of Public Health & 
Clinical Medicine, Umeå University, Umeå, Västerbotten, Sweden (Paul W Franks); OCDEM, 
Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom (Paul W 
Franks); Nephrology, Internal Medicine, Wake Forest School of Medicine, Winston-Salem, 
North Carolina (Barry I Freedman); Department of Genomics of Common Disease, Imperial 
College London, London, United Kingdom (Philippe Froguel); German Center for Diabetes 
Research (DZD e.V.), Neuherberg, Germany (Christian Gieger); Lifelines Cohort, Groningen, 
The Netherlands (Lifelines Cohort Study); Department of Genetics, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands (Pim van der Harst); Public 
Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina (Lynne E 
Wagenknecht); Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing 
Ophthalmology and Visual Science Key Lab, Beijing Tongren Hospital, Capital Medical 
University, Beijing, China (Ya Xing Wang); Health Data Research UK (HDR-UK) London at 
Imperial College London, London, United Kingdom (Paul Elliott); UK Dementia Research 
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Institute (UK-DRI) at Imperial College London, London, United Kingdom (Paul Elliott); 
Carolina Center of Genome Sciences, University of North Carolina, Chapel Hill, North Carolina 
(Kari E North); Public Health Sciences, Epidemiology and Prevention, Wake Forest University 
Health Sciences, Winston-Salem, North Carolina (Yongmei Liu); Cardiovascular Health 
Research Unit, Epidemiology, Medicine and Health Services, University of Washington, Seattle, 
Washington (Bruce Psaty); Kaiser Permanente Washington, Health Research Institute, Seattle, 
Washington Bruce Psaty); Harvard Medical School, Boston, Massachusetts (Paul M Ridker, 
Daniel I Chasman); Department of Medicine, Yong Loo Lin School of Medicine, National 
University of Singapore, Singapore, Singapore (Jianjun Liu, Rob M van Dam, E Shyong Tai); 
Public Health and Primary Care, Leiden University Medical Center, Leiden, Leiden (Dennis O 
Mook-Kanamori); Epidemiology, Tulane University School of Public Health and Tropical 
Medicine, New Orleans, Louisiana (Tanika N Kelly); Cardiology, Medicine, University of 
Mississippi Medical Center, Jackson, Mississippi (Ervin R Fox); WHI CCC, Fred Hutchinson 
Cancer Research Center, Seattle, Washington Jingmin Liu); Biostatistics, Preventive Medicine, 
University of Southern California, Los Angeles, California (W James Gauderman); NIHR Barts 
Cardiovascular Biomedical Research Unit, Queen Mary University of London, London, United 
Kingdom (Patricia B Munroe); and NHLBI Framingham Heart Study, Framingham, 
Massachusetts (L Adrienne Cupples). 
Equal contributions: Paul S de Vries, Michael R Brown, Amy R Bentley, Yun J Sung, Thomas 
W Winkler, Ioanna Ntalla contributed equally to the manuscript as junior authors. Patricia B 
Munroe, Kenneth Rice, Daniel I Chasman, L Adrienne Cupples, Dabeeru C Rao, Alanna C 
Morrison contributed equally to the manuscript as senior authors. 
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Funding: This work was supported by the National Heart, Lung, and Blood Institute grant 
R01HL118305. Infrastructure for the CHARGE Consortium is supported in part by the National 
Heart, Lung, and Blood Institute grant R01HL105756. American Heart Association Grant 
#17POST33350042 made it possible for Dr. de Vries to lead this project. Study-specific funding 
sources are provided below, starting with Stage 1 studies followed by Stage 2.  
AGES (Age Gene/Environment Susceptibility Reykjavik Study): This study has been funded by 
NIH contract N01-AG012100, the NIA Intramural Research Program, an Intramural Research 
Program Award (ZIAEY000401) from the National Eye Institute, an award from the National 
Institute on Deafness and Other Communication Disorders (NIDCD) Division of Scientific 
Programs (IAA Y2-DC_1004-02), Hjartavernd (the Icelandic Heart Association), and the 
Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics 
Committee, VSN: 00-063.   
ARIC (Atherosclerosis Risk in Communities) Study: The ARIC study is carried out as a 
collaborative study supported by National Heart, Lung, and Blood Institute contracts 
(HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, 
HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, 
HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and 
R01HL086694; National Human Genome Research Institute contract U01HG004402; and 
National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported 
by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH 
Roadmap for Medical Research. OR
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Baependi Heart Study (Brazil): The Baependi Heart Study was supported by Fundação de 
Amparo a Pesquisa do Estado de São Paulo (FAPESP) (Grant 2013/17368-0), Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Hospital Samaritano Society 
(Grant 25000.180.664/2011-35), through Ministry of Health to Support Program Institutional 
Development of the Unified Health System (SUS-PROADI). 
CARDIA (Coronary Artery Risk Development in Young Adults): The CARDIA Study is 
conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with 
the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), 
Northwestern University (HHSN268201300027C), University of Minnesota 
(HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and 
Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also 
partially supported by the Intramural Research Program of the National Institute on Aging. 
Genotyping was funded as part of the NHLBI Candidate-gene Association Resource (N01-HC-
65226) and the NHGRI Gene Environment Association Studies (GENEVA) (U01-HG004729, 
U01-HG04424, and U01-HG004446). This manuscript has been reviewed and approved by 
CARDIA for scientific content. 
CHS (Cardiovascular Health Study): This CHS research was supported by NHLBI contracts 
HHSN268201200036C, HHSN268200800007C, HHSN268200960009C, N01HC55222, 
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and 
NHLBI grants U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, 
R01HL120393 and R01HL130114 with additional contribution from the National Institute of 
Neurological Disorders and Stroke (NINDS). Additional support was provided through 
R01AG023629 from the National Institute on Aging (NIA). The provision of genotyping data 
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was supported in part by the National Center for Advancing Translational Sciences, CTSI grant 
UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease 
Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes 
Endocrinology Research Center.  
ERF (Erasmus Rucphen Family study): The ERF study as a part of EUROSPAN (European 
Special Populations Research Network) was supported by European Commission FP6 STRP 
grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European 
Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-
2007-201413 by the European Commission under the programme "Quality of Life and 
Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-
01254). The ERF study was further supported by ENGAGE consortium and CMSB. High-
throughput analysis of the ERF data was supported by joint grant from Netherlands Organisation 
for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 
047.017.043). ERF was further supported by the ZonMw grant (project 91111025).  
FamHS (Family Heart Study): The FamHS is funded by R01HL118305 and R01HL117078 
NHLBI grants, and 5R01DK07568102 and 5R01DK089256 NIDDK grant. 
FHS (Framingham Heart Study): This research was conducted in part using data and resources 
from the Framingham Heart Study of the National Heart Lung and Blood Institute of the 
National Institutes of Health and Boston University School of Medicine. The analyses reflect 
intellectual input and resource development from the Framingham Heart Study investigators 
participating in the SNP Health Association Resource (SHARe) project. This work was partially 
supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract 
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Nos. N01-HC-25195 and HHSN268201500001I) and its contract with Affymetrix, Inc for 
genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux 
Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the 
Department of Medicine at Boston University School of Medicine and Boston Medical Center. 
This research was partially supported by grant R01-DK089256 from the National Institute of 
Diabetes and Digestive and Kidney Diseases (MPIs: Ingrid B. Borecki, L. Adrienne Cupples, 
Kari North). 
GENOA (Genetic Epidemiology Network of Arteriopathy): Support for GENOA was provided by 
the National Heart, Lung and Blood Institute (HL119443, HL118305, HL054464, HL054457, 
HL054481, HL071917 and HL087660) of the National Institutes of Health. Genotyping was 
performed at the Mayo Clinic (Stephen T. Turner, MD, Mariza de Andrade PhD, Julie 
Cunningham, PhD).  
GenSalt (Genetic Epidemiology Network of Salt Sensitivity): The Genetic Epidemiology 
Network of Salt Sensitivity is supported by research grants (U01HL072507, R01HL087263, and 
R01HL090682) from the National Heart, Lung, and Blood Institute, National Institutes of 
Health, Bethesda, MD. 
HANDLS (Healthy Aging in Neighborhoods of Diversity across the Life Span): The Healthy 
Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study was supported by 
the Intramural Research Program of the NIH, National Institute on Aging and the National 
Center on Minority Health and Health Disparities (project # Z01-AG000513 and human subjects 
protocol number 09-AG-N248). Data analyses for the HANDLS study utilized the high-
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performance computational resources of the Biowulf Linux cluster at the National Institutes of 
Health, Bethesda, MD (http://biowulf.nih.gov; http://hpc.nih.gov)). 
Health ABC (Health, Aging, and Body Composition): Health ABC was funded by the National 
Institutes of Aging.  This research was supported by NIA contracts N01AG62101, 
N01AG62103, and N01AG62106. The GWAS was funded by NIA grant 1R01AG032098-01A1 
to Wake Forest University Health Sciences and genotyping services were provided by the Center 
for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the 
National Institutes of Health to The Johns Hopkins University, contract number 
HHSN268200782096C.  This research was supported in part by the Intramural Research 
Program of the NIH, National Institute on Aging. 
HERITAGE (Health, Risk Factors, Exercise Training and Genetics): The HERITAGE Family 
Study was supported by National Heart, Lung, and Blood Institute grant HL-45670. 
HUFS (Howard University Family Study):  The Howard University Family Study was supported 
by National Institutes of Health grants S06GM008016-320107 to Charles Rotimi and 
S06GM008016-380111 to Adebowale Adeyemo. Participant enrollment was carried out at the 
Howard University General Clinical Research Center, supported by National Institutes of Health 
grant 2M01RR010284. This research was supported in part by the Intramural Research Program 
of the Center for Research on Genomics and Global Health (CRGGH). The CRGGH is 
supported by the National Human Genome Research Institute, the National Institute of Diabetes 
and Digestive and Kidney Diseases, the Center for Information Technology, and the Office of 
the Director at the National Institutes of Health (Z01HG200362). Genotyping support was 
provided by the Coriell Institute for Medical Research. 
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HyperGEN (Hypertension Genetic Epidemiology Network): The hypertension network is funded 
by cooperative agreements (U10) with NHLBI:  HL54471, HL54472, HL54473, HL54495, 
HL54496, HL54497, HL54509, HL54515, and 2 R01 HL55673-12. The study involves: 
University of Utah: (Network Coordinating Center, Field Center, and Molecular Genetics Lab); 
Univ. of Alabama at Birmingham: (Field Center and Echo Coordinating and Analysis Center); 
Medical College of Wisconsin: (Echo Genotyping Lab); Boston University: (Field Center); 
University of Minnesota: (Field Center and Biochemistry Lab); University of North Carolina: 
(Field Center); Washington University: (Data Coordinating Center); Weil Cornell Medical 
College: (Echo Reading Center); National Heart, Lung, & Blood Institute. For a complete list of 
HyperGEN Investigators:  http://www.biostat.wustl.edu/hypergen/Acknowledge.html 
CROATIA-Korcula: CROATIA-Korcula (CR-Korcula) was funded by the Medical Research 
Council UK, The Croatian Ministry of Science, Education and Sports (grant 216-1080315-0302), 
the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-
018947) and the Croatian Science Foundation (grant 8875). The SNP genotyping for the 
CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, 
Germany. 
CROATIA-Vis: CROATIA-Vis (CR-Vis) was funded by the Medical Research Council UK, The 
Croatian Ministry of Science, Education and Sports (grant 216-1080315-0302), the European 
Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947) and 
the Croatian Science Foundation (grant 8875). The SNP genotyping for the CROATIA-Vis 
cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research 
Facility at the Western General Hospital, Edinburgh, Scotland. 
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GS:SFHS: Generation Scotland received core support from the Chief Scientist Office of the 
Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council 
[HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core 
Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was 
funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic 
Award “STratifying Resilience and Depression Longitudinally” (STRADL) Reference 
104036/Z/14/Z). Ethics approval for the study was given by the NHS Tayside committee on 
research ethics (reference 05/S1401/89).  
JHS (Jackson Heart Study): The Jackson Heart Study is supported by contracts 
HSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, 
HHSN268201300050C from the National Heart, Lung, and Blood Institute on Minority Health 
and Health Disparities.  
MESA (Multi-Ethnic Study of Atherosclerosis): This research was supported by the Multi-Ethnic 
Study of Atherosclerosis (MESA) contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, 
N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-
95167, N01-HC-95168, N01-HC-95169, by grant HL071205 and by  UL1-DR-001079 from 
NCRR .  Funding for MESA SHARe genotyping was provided by NHLBI Contract N02-HL-6-
4278. This publication was partially developed under a STAR research assistance agreement, 
No. RD831697 (MESA Air), awarded by the U.S Environmental Protection Agency. The 
provision of genotyping data was supported in part by the National Center for Advancing 
Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and 
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Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern 
California Diabetes Endocrinology Research Center.   
NEO (The Netherlands Epidemiology of Obesity study): The genotyping in the NEO study was 
supported by the Centre National de Génotypage (Paris, France), headed by Jean-Francois 
Deleuze. The NEO study is supported by the participating Departments, the Division and the 
Board of Directors of the Leiden University Medical Center, and by the Leiden University, 
Research Profile Area Vascular and Regenerative Medicine. Dennis Mook-Kanamori is 
supported by Dutch Science Organization (ZonMW-VENI Grant 916.14.023). 
Pelotas Birth Cohort Study (The 1982 Pelotas Birth Cohort Study, Brazil): The 1982 Pelotas 
Birth Cohort Study is conducted by the Postgraduate Program in Epidemiology at Universidade 
Federal de Pelotas with the collaboration of the Brazilian Public Health Association 
(ABRASCO). From 2004 to 2013, the Wellcome Trust supported the study. The International 
Development Research Center, World Health Organization, Overseas Development 
Administration, European Union, National Support Program for Centers of Excellence 
(PRONEX), the Brazilian National Research Council (CNPq), and the Brazilian Ministry of 
Health supported previous phases of the study. 
Genotyping of 1982 Pelotas Birth Cohort Study participants was supported by the Department of 
Science and Technology (DECIT, Ministry of Health) and National Fund for Scientific and 
Technological Development (FNDCT, Ministry of Science and Technology), Funding of Studies 
and Projects (FINEP, Ministry of Science and Technology, Brazil), Coordination of 
Improvement of Higher Education Personnel (CAPES, Ministry of Education, Brazil). 
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RS (Rotterdam Study): The Rotterdam Study is funded by Erasmus Medical Center and Erasmus 
University, Rotterdam, Netherlands Organization for the Health Research and Development 
(ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, 
Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission 
(DG XII), and the Municipality of Rotterdam. The generation and management of GWAS 
genotype data for the Rotterdam Study was executed by the Human Genotyping Facility of the 
Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The 
Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific 
Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the 
Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly 
(014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for 
Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 
050-060-810.  
SCHS-CHD (Singapore Chinese Health Study - Coronary Heart Disease): The Singapore 
Chinese Health Study is supported by the National Institutes of Health, USA (RO1 CA144034 
and UM1 CA182876), the nested case-control study of myocardial infarction by the Singapore 
National Medical Research Council (NMRC 1270/2010) and genotyping by the HUJ-CREATE 
Programme of the National Research Foundation, Singapore (Project Number 370062002). 
SCES (Singapore Chinese Eye Study), SiMES (Singapore Malay Eye Study), (SINDI) Singapore 
Indian Eye Study: The Singapore Malay Eye Study (SiMES), the Singapore Indian Eye Study 
(SINDI), and the Singapore Chinese Eye Study (SCES) are supported by the National Medical 
Research Council (NMRC), Singapore (grants 0796/2003, 1176/2008, 1149/2008, 
STaR/0003/2008, 1249/2010, CG/SERI/2010, CIRG/1371/2013, and CIRG/1417/2015), and 
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Biomedical Research Council (BMRC), Singapore (08/1/35/19/550 and 09/1/35/19/616). Ching-
Yu Cheng is supported by an award from NMRC (CSA/033/2012). The Singapore Tissue 
Network and the Genome Institute of Singapore, Agency for Science, Technology and Research, 
Singapore provided services for tissue archival and genotyping, respectively.  
SP2 (Singapore Prospective Study Program): SP2 is supported by the individual research grant 
and clinician scientist award schemes from the National Medical Research Council and the 
Biomedical Research Councils of Singapore. 
WGHS (Women’s Genome Health Study): The WGHS is supported by the National Heart, Lung, 
and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 
and UM1CA182913), with collaborative scientific support and funding for genotyping provided 
by Amgen. 
WHI (Women’s Health Initiative): The WHI program is funded by the National Heart, Lung, and 
Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services 
through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, 
HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.  
AA-DHS (African American Diabetes Heart Study): The investigators acknowledge the 
cooperation of our Diabetes Heart Study (DHS) and AA-DHS participants. This work was 
supported by NIH R01 DK071891, R01 HL092301 and the General Clinical Research Center of 
Wake Forest School of Medicine M01-RR-07122. 
Airwave (The Airwave Health Monitoring Study): The study is funded by the Home Office 
(Grant number 780-TETRA) with additional support from the National Institute for Health 
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Research (NIHR), Imperial College Healthcare NHS Trust (ICHNT) and Imperial College 
Biomedical Research Centre (BRC). The study has ethical approval from the National Health 
Service Multi-site Research Ethics Committee (MREC/13/NW/0588). This work used computing 
resources provided by the MRC- funded UK MEDical Bioinformatics partnership programme 
(UK MED-BIO) (MR/L01632X/1). P.E. would like to acknowledge support from the Medical 
Research Council and Public Health England for the MRC-PHE Centre for Environment and 
Health (MR/L01341X/1) and from the NIHR Health Protection Research Unit in Health Impact 
of Environmental Hazards (HPRU-2012-10141). 
ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial): The ASCOT study was supported by 
Pfizer, New York, NY, USA for the ASCOT study and the collection of the ASCOT DNA 
repository; by Servier Research Group, Paris, France; and by Leo Laboratories, Copenhagen, 
Denmark. We thank all ASCOT trial participants, physicians, nurses, and practices in the 
participating countries for their important contribution to the study. In particular we thank Clare 
Muckian and David Toomey for their help in DNA extraction, storage, and handling. Genotyping 
was funded by the CNG, MRC and the National Institutes of Health Research (NIHR). This 
work forms part of the research programme of the NIHR Cardiovascular Biomedical Research 
Unit at Barts and The London, QMUL. H.R.W, M.J.C and P.B.M. wishes to acknowledge the 
NIHR Cardiovascular Biomedical Research Unit at Barts and The London, Queen Mary 
University of London, UK for support. 
BBJ (Biobank Japan Project): BioBank Japan project is supported by the Japan Agency for 
Medical Research and Development and by the Ministry of Education, Culture, Sports, Sciences 
and Technology of the Japanese government. 
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BES (Beijing Eye Study): BES was supported by the National Key Laboratory Fund, Beijing, 
China. 
BRIGHT (British Genetics of Hypertension): This work was supported by the Medical Research 
Council of Great Britain (grant number G9521010D) and the British Heart Foundation (grant 
number PG/02/128). The BRIGHT study is extremely grateful to all the patients who participated 
in the study and the BRIGHT nursing team. This work forms part of the research program of the 
National Institutes of Health Research (NIHR Cardiovascular Biomedical Research) 
Cardiovascular Biomedical Unit at Barts and The London, QMUL. 
CAGE-Amagasaki (Cardio-metabolic Genome Epidemiology Network, Amagasaki Study): The 
CAGE Network studies were supported by grants for the Core Research for Evolutional Science 
and Technology (CREST) from the Japan Science Technology Agency; the Program for 
Promotion of Fundamental Studies in Health Sciences, National Institute of Biomedical 
Innovation Organization (NIBIO); and the Grant of National Center for Global Health and 
Medicine (NCGM). 
DESIR (Data from an Epidemiological Study on the Insulin Resistance): The DESIR Study 
Group is composed of Inserm-U1018 (Paris: B. Balkau, P. Ducimetière, E. Eschwège), Inserm-
U367 (Paris: F. Alhenc-Gelas), CHU d‟Angers (A. Girault), Bichat Hospital (Paris: F. Fumeron, 
M. Marre, R. Roussel), CHU de Rennes (F. Bonnet), CNRS UMR-8199 (Lille: A. Bonnefond, P. 
Froguel), Medical Examination Services (Alençon, Angers, Blois, Caen, Chartres, Chateauroux, 
Cholet, LeMans, Orléans and Tours), Research Institute for General Medicine (J. Cogneau), the 
general practitioners of the region and the Cross- Regional Institute for Health (C. Born, E. 
Caces, M. Cailleau, N. Copin, J.G. Moreau, F. Rakotozafy, J. Tichet, S. Vol). The DESIR study 
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was supported by Inserm contracts with CNAMTS, Lilly, Novartis Pharma and Sanofi-aventis, 
and by Inserm (Réseaux en Santé Publique, Interactions entre les déterminants de la santé, 
Cohortes Santé TGIR 2008), the Association Diabète Risque Vasculaire, the Fédération 
Française de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS, Société 
Francophone du Diabète, Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, 
Merck Santé, Novo Nordisk, Pierre Fabre, Roche and Topcon. 
DFTJ (Dongfeng-Tongji Cohort Study): This work was supported by grants from the National 
Basic Research Program grant (2011CB503800), the Programme of Introducing Talents of 
Discipline, the grants from the National Natural Science Foundation (grant NSFC-81473051, 
81522040 and 81230069), and the Program for the New Century Excellent Talents in University 
(NCET-11-0169). 
DHS (Diabetes Heart Study): This study was supported by the National Institutes of Health 
through HL67348 and HL092301. 
DR’s EXTRA (Dose Responses to Exercise Training): The study was supported by grants from 
Ministry of Education and Culture of Finland (722 and 627; 2004-2010); Academy of Finland 
(102318, 104943, 123885, 211119); European Commission FP6 Integrated Project 
(EXGENESIS), LSHM-CT-2004-005272; City of Kuopio; Juho Vainio Foundation; Finnish 
Diabetes Association; Finnish Foundation for Cardiovascular Research; Kuopio University 
Hospital; Päivikki and Sakari Sohlberg Foundation; Social Insurance Institution of Finland 
4/26/2010. 
EGCUT (Estonian Genome Center - University of Tartu (Estonian Biobank)): This study was 
supported by EU H2020 grants 692145, 676550, 654248, Estonian Research Council Grant 
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IUT20-60, NIASC, EIT – Health and NIH-BMI Grant No: 2R01DK075787-06A1 and EU 
through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012 
GENTRANSMED. 
EPIC (European Prospective Investigation into Cancer and Nutrition): The EPIC Norfolk Study 
is funded by Cancer Research, United Kingdom, British Heart Foundation, the Medical Research 
Council, the Ministry of Agriculture, Fisheries and Food, and the Europe against Cancer 
Programme of the Commission of the European Communities.  
FENLAND (The Fenland Study): The Fenland Study is funded by the Wellcome Trust and the 
Medical Research Council (MC_U106179471). We further acknowledge support from the 
Medical research council (MC_UU_12015/1). 
FUSION (Finland-United States Investigation of NIDDM Genetics): The FUSION study was 
supported by DK093757, DK072193, DK062370, and ZIA-HG000024. Genotyping was 
conducted at the Genetic Resources Core Facility (GRCF) at the Johns Hopkins Institute of 
Genetic Medicine. 
GeneSTAR (Genetic Studies of Atherosclerosis Risk): GeneSTAR was supported by National 
Institutes of Health grants from the National Heart, Lung, and Blood Institute (HL49762, 
HL59684, HL58625, HL071025, U01 HL72518, HL087698, HL092165, HL099747, and 
K23HL105897), National Institute of Nursing Research (NR0224103), National Institute of 
Neurological Disorders and Stroke (NS062059), and by grants from the National Center for 
Research Resources to the Johns Hopkins General Clinical Research Center (M01-RR000052) 
and the Johns Hopkins Institute for Clinical & Translational Research (UL1 RR 025005). 
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GLACIER (Gene x Lifestyle Interactions and Complex Traits Involved in Elevated Disease Risk): 
The current study was supported by Novo Nordisk (PWF), the Swedish Research Council 
(PWF), the Swedish Heart Lung Foundation (PWF), the European Research Council (PWF), and 
the Skåne Health Authority (PWF). 
GRAPHIC (Genetic Regulation of Arterial Pressure of Humans in the Community): The 
GRAPHIC Study was funded by the British Heart Foundation (BHF/RG/2000004). This work 
falls under the portfolio of research supported by the NIHR Leicester Cardiovascular Biomedical 
Research Unit. CPN and NJS are funded by the BHF and NJS is a NIHR Senior Investigator. 
HCHS/SOL (Hispanic Community Health Study/ Study of Latinos): The baseline examination of 
HCHS/SOL was supported by contracts from the National Heart, Lung, and Blood Institute 
(NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-
HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University 
(N01-HC65236), and San Diego State University (N01-HC65237). The National Institute on 
Minority Health and Health Disparities, National Institute on Deafness and Other 
Communication Disorders, National Institute of Dental and Craniofacial Research (NIDCR), 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of 
Neurological Disorders and Stroke, and NIH Office of Dietary Supplements additionally 
contributed funding to HCHS/SOL. The Genetic Analysis Center at the University of 
Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and 
MOD03). Additional analysis support was provided by 1R01DK101855-01 and 
13GRNT16490017. Genotyping was also supported by National Center for Advancing 
Translational Sciences UL1TR000124 and NIDDK DK063491 to the Southern California 
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Diabetes Endocrinology Research Center. This research was also supported in part by the 
Intramural Research Program of the NIDDK, contract no. HHSB268201200054C, and Illumina. 
HRS (Health & Retirement Study): HRS is supported by the National Institute on Aging (NIA 
U01AG009740 and R03 AG046389).  Genotyping was funded separately by NIA (RC2 
AG036495, RC4 AG039029).  Our genotyping was conducted by the NIH Center for Inherited 
Disease Research (CIDR) at Johns Hopkins University.  Genotyping quality control and final 
preparation of the data were performed by the Genetics Coordinating Center at the University of 
Washington. 
HyperGEN-AXIOM (Hypertension Genetic Epidemiology Network): The study was support by 
the National Institutes of Health, the National Heart, Lung, Blood Institute grant HL086718. 
INGI-CARL (Italian Network Genetic Isolates): This study was partially supported by Regione 
FVG (L.26.2008) and Italian Ministry of Health (GR-2011-02349604). 
INGI-FVG (Italian Network Genetic Isolates): This study was partially supported by Regione 
FVG (L.26.2008) and Italian Ministry of Health (GR-2011-02349604). 
InterAct (The EPIC-InterAct Case-Cohort Study): The InterAct study received funding from the 
European Union (Integrated Project LSHM-CT-2006-037197 in the Framework Programme 6 of 
the European Community). 
IRAS (Insulin Resistance Atherosclerosis Study): The IRAS is supported by the National Heart 
Lung Institute (HL047887, HL047889, HL047890, and HL47902). Genotyping for this study 
was supported by the GUARDIAN Consortium with grant support from the National Institute of 
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Diabetes and Digestive and Kidney Diseases (NIDDK; DK085175) and in part by 
UL1TR000124 (CTSI) and DK063491 (DRC).  
IRAS Family Study (Insulin Resistance Atherosclerosis Study): The IRASFS is supported by the 
National Heart Lung and Blood Institute (HL060944, HL061019, and HL060919). Genotyping 
for this study was supported by the GUARDIAN Consortium with grant support from the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; DK085175) and in 
part by UL1TR000124 (CTSI) and DK063491 (DRC).  
KORA (Cooperative Health Research in the Augsburg Region): The KORA study was initiated 
and financed by the Helmholtz Zentrum München – German Research Center for Environmental 
Health, which is funded by the German Federal Ministry of Education and Research (BMBF) 
and by the State of Bavaria. Furthermore, KORA research was supported within the Munich 
Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of 
LMUinnovativ. 
LBC1936 (Lothian Birth Cohort 1936): Phenotype collection was supported by Age UK (The 
Disconnected Mind project). Genotyping was funded by the BBSRC (BB/F019394/1). The work 
was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive 
Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative 
(MR/K026992/1). Funding from the BBSRC and Medical Research Council (MRC) is gratefully 
acknowledged. 
LifeLines (Netherlands Biobank): The Lifelines Cohort Study, and generation and management 
of GWAS genotype data for the Lifelines Cohort Study is supported by the Netherlands 
Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure 
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Enhancing Fund (FES) of the Dutch government, the Ministry of Economic Affairs, the Ministry 
of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern 
Netherlands Collaboration of Provinces (SNN), the Province of Groningen, University Medical 
Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes 
Research Foundation. 
LLFS (The Long Life Family Study): The study is supported by the National Institute on Aging 
(NIA) grant U01AG023746. 
LOLIPOP (London Life Sciences Prospective Population Study): The LOLIPOP study is 
supported by the National Institute for Health Research (NIHR) Comprehensive Biomedical 
Research Centre Imperial College Healthcare NHS Trust, the British Heart Foundation 
(SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome Trust 
(084723/Z/08/Z), the NIHR (RP-PG-0407-10371), European Union FP7 (EpiMigrant, 279143), 
and Action on Hearing Loss (G51).  
Loyola GxE (Kingston Gene-by-environment; subset of International Collaborative Study of 
Hypertension in Blacks (ICSHIB)): The Loyola GxE project was supported by NIH Grant 
R01HL53353. 
Loyola SPT (Spanish Town; subset of International Collaborative Study of Hypertension in 
Blacks (ICSHIB)): The Loyola SPT project was supported by NIH Grant R01HL53353. 
METSIM (Metabolic Syndrome In Men): The METSIM study was supported by the Academy of 
Finland (contract 124243), the Finnish Heart Foundation, the Finnish Diabetes Foundation, 
Tekes (contract 1510/31/06), and the Commission of the European Community (HEALTH-F2-
OR
IG
IN
AL
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/advance-article-abstract/doi/10.1093/aje/kw
z005/5304469 by Q
ueen M
ary U
niversity of London user on 25 February 2019
67 
 
2007 201681), and the US National Institutes of Health grants DK093757, DK072193, 
DK062370, and ZIA- HG000024.  Genotyping was conducted at the Genetic Resources Core 
Facility (GRCF) at the Johns Hopkins Institute of Genetic Medicine. 
NESDA (Netherlands Study of Depression and Anxiety): The infrastructure for the NESDA study 
is funded through the Geestkracht programme of the Dutch Scientific Organization (ZON-MW, 
grant number 10-000-1002) and matching funds from participating universities and mental health 
care organizations. Genotyping in NESDA was funded by the Genetic Association Information 
Network (GAIN) of the Foundation for the US National Institutes of Health. Statistical analyses 
were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is 
financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with 
a supplement from the Dutch Brain Foundation. 
OBA (French obese cases): The obese French adults were recruited by the laboratory "Integrated 
Genomics and Metabolic Diseases Modeling" (UMR 8199 CNRS / Université de Lille 2 / Institut 
Pasteur de Lille) of Pr. Philippe Froguel. 
PREVEND (The Prevention of REnal and Vascular ENd stage Disease study): PREVEND 
genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project grant 
GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant 
2R01LM010098), The Netherlands organization for health research and development (NWO-
Groot grant 175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 90.700.441). 
PROCARDIS (Precocious Coronary Artery Disease): PROCARDIS was supported by the 
European Community Sixth Framework Program (LSHM-CT- 2007-037273), AstraZeneca, the 
British Heart Foundation, the Swedish Research Council, the Knut and Alice Wallenberg 
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TABLES 
Table 1. Layout of the Overall Study Design.  
Stage 
No. in Each Ancestry Group 
European African Asian Hispanic Brazilian Meta-Analysis 
1 89,893 20,989 12,450 3,994 0 127,326 
2a 136,986 4,475 108,431 13,714 3,652 267,258 
Totalb 226,879 25,464 120,881 17,708 3,652 394,584 
For each lipid trait, association analyses were performed, accounting for the two alcohol consumption variables: “current drinker” 
status and “regular drinker”. For each ancestry group, study-specific results were combined to perform the 1 degree of freedom (DF) 
test for an interaction effect and the 2 DF joint test of genetic main effect and interaction with drinking exposure. Individuals from five 
ancestry groups were included: European, African, Asian, Hispanic, and Brazilian. 
a
Variants selected for follow-up at P ≤ 1x10-6 
using 1 DF interaction and 2 DF joint tests. 
b
Variants significant at P ≤ 5x10-8 using 2 DF joint or 1 DF interaction test. 
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Table 2. Novel Loci Discovered in the Combined Analysis of Stages 1 and 2 Using the 2 DF Model that Jointly Tests Main and 
Interaction Effects. 
rsID Chr:Position Allelesa Freq Closest Gene(s) 
Main 
Effectb 
Interaction 
Effectb 
Joint P-
valueb 
Joint FDR 
q-valueb 
Interaction 
P-valuec 
Heterogeneity 
P-valued 
Most Significant 2 DF Model 
rs190528931e 11:63911273 A/C 0.04 MACROD1 0.0109 -0.0023 1.9×10-16 3.6×10
-11 0.32 0.96 META - HDL-C – CURDRINK 
rs7904973e 10:124693587 T/G 0.55 C10orf88 0.9200 -0.1500 1.9×10-15 3.5×10
-10 0.38 0.89 META - LDL-C - CURDRINK 
rs73729083 7:137559799 C/T 0.91 CREB3L2 4.0100 0.6500 8.2×10 -15 1.4×10-9 0.57 0.22 META - LDL-C - CURDRINK 
rs80080062 3:185812169 G/C 0.87 ETV5 0.0061 0.0031 1.1×10-12 1.7×10
-7 0.38 0.85 META - HDL-C - REGDRINK 
rs7140110 13:114544024 C/T 0.73 GAS6-AS1 -0.0100 -0.0040 3.4×10-12 5.1×10
-7 0.19 0.42 META - TG - CURDRINK 
rs34311866 4:951947 C/T 0.83 TMEM175 -0.0200 0.0040 1.5×10-11 2.1×10-6 0.42 0.90 EUR - TG – CURDRINK 
rs2911971 8:6607634 G/C 0.34 AGPAT5 -0.7500 0.0100 7.5×10-11 1.1×10
-5 0.53 0.49 META - LDL-C - CURDRINK 
rs56076449 5:132442190 G/T 0.79 HSPA4 / FSTL4 0.0130 -0.0020 9.3×10-11 1.3×10
-5 0.80 0.80 META - TG - REGDRINK 
rs41274050e 10:52573772 T/C 0.01 A1CF 0.1080 -0.0310 9.6×10-10 1.3×10-4 0.62 1.00 EUR - TG – REGDRINK 
rs7035578 9:78745177 A/G 0.15 PCSK5 -1.2700 0.0800 1.2×10-9 1.6×10
-4 0.70 0.82 EUR - LDL-C - CURDRINK 
rs201445483 2:17890087 I/D 0.83 SMC6 1.4300 0.6800 4.7×10-9 6.0×10
-4 0.17 0.46 META - LDL-C - CURDRINK 
rs72729610 4:154190965 G/A 0.86 TRIM2 0.0075 -0.0036 5.6×10-9 7.2×10-4 0.08 0.26 META - HDL-C - REGDRINK 
rs143528679 4:124558378 G/A 0.10 
SPRY1 / 
LINC01091 
-1.2000 -5.6300 6.3×10-9 8.0×10
-4 6.4×10-4 0.10 AFR - LDL-C - CURDRINK 
rs2111622e 2:53984823 G/A 0.77 
ASB3 / GPR75-
ASB3 
0.0008 -0.0072 7.9×10-9 9.9×10
-4 0.01 0.12 EUR - HDL-C - CURDRINK 
rs13284665 9:131513370 G/A 0.88 ZER1 1.9900 -0.8900 1.1×10-8 1.3×10
-3 0.35 0.89 EUR - LDL-C - CURDRINK 
rs4898521 12:49755162 A/T 0.95 
DNAJC22 / 
SPATS2 
0.0179 -0.0107 1.3×10-8 1.7×10
-3 0.06 1.00 EUR - HDL-C  - REGDRINK 
rs6063050 20:45604240 C/T 0.75 EYA2 0.0110 0.0000 2.9×10-8 3.6×10
-3 0.30 0.39 META - TG - CURDRINK 
rs2963472 5:157999022 A/G 0.21 
LOC101927697 
/ EBF1 
0.0140 -0.0020 3.5×10-8 4.2×10
-3 0.96 0.23 EUR - TG – REGDRINK 
rsID: Reference SNP ID. Chr: Chromosome number. Freq: Frequency of the coded allele. FDR: False discovery rate. DF: Degrees of 
freedom. HDL-C: High-density lipoprotein cholesterol. LDL-C: Low-density lipoprotein cholesterol. TG: Triglycerides. AFR: African 
ancestry. EUR: European ancestry. META: trans-ancestry meta-analysis. CURDRINK: alcohol consumption categorized into drinkers 
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and non-drinkers. REGDRINK: alcohol consumption categorized into regular drinkers and not regular drinkers. 
a
The Alleles column 
reports the coded/non-coded alleles. 
b
These estimates pertain to the 2 DF joint test of main and interaction effects. 
c
These P-values 
pertain to 1 DF tests of interaction effects. 
d
The Heterogeneity P-value column indicates the significance of the Stage 1 heterogeneity 
across ancestry groups in the most significant 2 DF Model. 
e
These loci were also discovered by a concurrent association study focused 
on exonic variants (37).  
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FIGURE LEGENDS 
Figure 1. Venn Diagram Showing the Distribution of Genome-wide Significant Associations at 
the 147 Identified Loci Among Lipid Traits. HDL-C: High-density lipoprotein cholesterol. LDL-
C: Low-density lipoprotein cholesterol. 
 
Figure 2. Heat Map of the Significance and Effect Direction of Index Variants at the 18 Novel 
Loci for the Three Lipid Traits. 
For each combination of index variant and lipid trait, the effect direction and P-value of the most 
significant association is shown. For example: the 11:63911273 variant was most significantly 
associated with high-density lipoprotein cholesterol in the trans-ancestry meta-analysis, using the 
current drinker alcohol consumption variable. Shades of purple and yellow represent negative 
and positive directions of effect, respectively, while associations of either direction with P-value 
> 0.05 are white. Effect +: the direction of effect is greater than or equal to zero. Effect –: the 
direction of effect is less than zero. 
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